ライフサイエンスコーパス: mucinous

1 t (496 serous invasive, 139 endometrioid, 86 mucinous).

2 rade serous (HGS), 2,100 endometrioid, 1,591 mucinous, 1,034 clear cell, and 1,016 low-grade serous,

3 ial ovarian cancer, 402 were serous, 74 were mucinous, 106 were endometrioid, and 127 were of other c

4 ntified (3,378 serous, 606 endometrioid, 331 mucinous, 269 clear cell, 1,000 other).

5 was noted between endometriosis and risk of mucinous (31 [6.0%] of 516 cases, 1.02, 0.69-1.50, p=0.9

6 of 1140 cases, 1.20, 0.95-1.52, p=0.12, and mucinous 65 [8.5%] of 767 cases, 1.12, 0.84-1.48, p=0.45

7 istologic diagnosis of the cystic lesion (68 mucinous, 7 serous, 27 inflammatory, 5 endocrine, and 5

8 ficantly worse cancer-specific survival than mucinous adenocarcinoma and nonmucinous adenocarcinoma p

9 The solid malignancies included 2 cases of mucinous adenocarcinoma of the colon, 1 each of metastat

10 Mucinous adenocarcinoma of the lung is a subtype of high

11 mary cutaneous mucinous carcinoma," "primary mucinous adenocarcinoma of the skin," "primary mucinous

12 the model also displayed a low incidence of mucinous adenocarcinoma, a rare variant type of human pr

13 lly have cystic components; and (d) invasive mucinous adenocarcinoma, histopathologically showing lep

14 impact, especially in patients with stage IV mucinous adenocarcinoma.

15 d between the right and left colon; 62% were mucinous adenocarcinoma.

16 al transition program leading to an invasive mucinous adenocarcinoma.

17 alveolar carcinomas are now called "invasive mucinous adenocarcinoma." Because the lung cancer field

18 Less frequent subtypes include mucinous adenocarcinomas (MAC) and signet-ring cell carc

19 Mucinous adenocarcinomas develop 5 to 30 weeks after inf

20 tage IV moderately and poorly differentiated mucinous adenocarcinomas have distinctly different CSS a

21 combine moderately and poorly differentiated mucinous adenocarcinomas into a single mucinous high-gra

22 prognostic impact of histological grade for mucinous adenocarcinomas is primarily restricted to stag

23 Trousseau syndrome often occurs with mucinous adenocarcinomas, which secrete abnormally glyco

24 ifferentiated histology were more common for mucinous adenocarcinomas.

25 ce that were phenotypically similar to human mucinous adenocarcinomas.

26 istant microthrombi in patients with occult, mucinous adenocarcinomas.

27 of PI3K results in hyperplasia and invasive mucinous adenocarcinomas.

28 ppendiceal adenocarcinomas, consisting of 17 mucinous and 11 nonmucinous carcinomas.

29 pendiceal carcinomas including 54% (7/13) of mucinous and 63% (5/8) of nonmucinous carcinomas.

30 mong colorectal adenocarcinomas, 10%-15% are mucinous and have worse prognoses than nonmucinous ones.

31 gnostic approach should focus on identifying mucinous and malignant cysts.

32 A significant difference between benign mucinous and malignant mucinous cysts was observed (p =

33 quent (32.1%, versus 12.1% in DGCs), as were mucinous and neuroendocrine carcinomas, carcinoma with l

34 romise in the ability to distinguish between mucinous and nonmucinous cysts.

35 ave improved accuracy to distinguish between mucinous and nonmucinous cysts.

36 Though overall CSS was similar for mucinous and nonmucinous subtypes, differences in stage

37 YC amplification was detected in both of the mucinous and the Brenner components; MYC amplification a

38 fering associations for hormonal factors and mucinous and tubular cancers suggest etiologies distinct

39 l ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as

40 pseudocysts), benign (serous), premalignant (mucinous), and malignant (mucinous) lesions.

41 , 836 lobular, 639 mixed ductal-lobular, 216 mucinous, and 132 tubular breast cancers were diagnosed.

42 ssociated with decreased risk of clear cell, mucinous, and endometrioid subtype, but not with the mos

43 marker to differentiate non-mucinous, benign mucinous, and malignant mucinous cysts.

44 have a major prognostic impact in metastatic mucinous appendiceal adenocarcinomas, the prognostic imp

45 ic cyst fluid biomarker to differentiate non-mucinous, benign mucinous, and malignant mucinous cysts.

46 ours and the large size and heterogeneity of mucinous borderline tumours which may result in an invas

47 Former mucinous bronchioloalveolar carcinomas are now called "i

48 types of ovarian cancer but not in HOSE and mucinous cancer cells.

49 The relative risks for ductal and mucinous cancers were 1.63 (95% CI 1.55-1.72) and 1.58 (

50 -lobular, 492 tubular, 71 medullary, and 148 mucinous cancers; and 1913 (14%) were in situ, including

51 ines are not available for primary cutaneous mucinous carcinoma (PCMC).

52 Invasive mucinous carcinoma of the ovary (mucinous epithelial ova

53 ma) lesions and one precancerous (pancreatic mucinous carcinoma) lesion were detected.

54 10 with low-grade serous carcinoma, 207 with mucinous carcinoma, 484 with endometrioid carcinoma, and

55 Search terms were "primary cutaneous mucinous carcinoma," "primary mucinous adenocarcinoma of

56 rom an in situ lesion to a classic, invasive mucinous carcinoma.

57 ferentiation and the other was pure invasive mucinous carcinoma.

58 s; ii) low-grade serous carcinomas; and iii) mucinous carcinomas and malignant Brenner tumors.

59 n situ component, 7 (44%) were pure invasive mucinous carcinomas, and 5 (31%) demonstrated both growt

60 us carcinomas, type I tumors are composed of mucinous carcinomas, endometrioid carcinomas, malignant

61 r the diagnosis and the prognosis of colonic mucinous carcinomas.

62 ous, low-grade endometrioid, clear-cell, and mucinous carcinomas.

63 serous carcinomas from high-grade serous and mucinous carcinomas.

64 hemotherapy treatment (P < .001), peritoneal mucinous carcinomatosis (PMCA) histopathologic subtype (

65 ma peritonei (PMP) is an uncommon peritoneal mucinous carcinomatosis confined to the peritoneal cavit

66 cases from 65% (based on CA125) to 82%, and mucinous cases from 44% to 88%.

67 /-) prostatic grafts also contained atypical mucinous cells, which appeared to differentiate from lum

68 ing high and low grade serous, endometrioid, mucinous, clear cell, and granulosa cell carcinomas and

69 We recorded no significant associations for mucinous, clear-cell, or low-grade serous carcinoma.

70 e tumors were strikingly similar to invasive mucinous colon cancers in humans.

71 PDG are distinct gland-like mucinous compartments with a distinct molecular signatur

72 indolent tumor types (islet cell tumors and mucinous cystadenocarcinoma).

73 rozygous WT/Trp53(R172H) mice also presented mucinous cystadenocarcinomas at 12 weeks of age, recapit

74 ), solid pseudopapillary neoplasms(12%), and mucinous cystadenomas (6%).

75 is a very good marker for the presence of a mucinous cystic lesion, it is not an indicator of malign

76 accurate test available for the diagnosis of mucinous cystic lesions of the pancreas.

77 rent understanding of the natural history of mucinous cystic lesions, and includes the current use an

78 epithelial = 1, simple = 1) 25 premalignant (mucinous cystic neoplasm =16, intraductal papillary muci

79 raductal papillary mucinous neoplasm [IPMN], mucinous cystic neoplasm [MCN]).

80 2012 international consensus guidelines for mucinous cystic neoplasm and intraductal papillary mucin

81 lack of ovarian-type stroma in a pancreatic mucinous cystic neoplasm and the presence of pleomorphic

82 uctal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm were updated in 2012, incorpora

83 Pathological examination revealed a mucinous cystic neoplasm with a component of an undiffer

84 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplasm) lesions have malignant potenti

85 AC, ampullary carcinoma, cholangiocarcinoma, mucinous cystic neoplasm, chronic inflammation, and chro

86 Mucinous cystic neoplasm-associated adenocarcinoma appea

87 Pathologies included: 35 mucinous cystic neoplasms (adenoma 28, borderline 7), 22

88 Pancreatic mucinous cystic neoplasms (MCNs) harbor malignant potent

89 Mucinous cystic neoplasms (MCNs) of the pancreas are unc

90 ductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), and solid pseudopapill

91 uid samples were obtained from patients with mucinous cystic neoplasms (n=17), intraductal papillary

92 ical characteristics of intrahepatic biliary mucinous cystic neoplasms and to establish eligible diag

93 Intrahepatic biliary mucinous cystic neoplasms are rare and preoperative diag

94 Intrahepatic biliary mucinous cystic neoplasms are rare hepatic tumors and ac

95 novel pancreatic lesion resembling low-grade mucinous cystic neoplasms in humans.

96 discriminated mucin-producing cystic tumors (mucinous cystic neoplasms+intraductal papillary mucinous

97 intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, have the potential to progres

98 ts and simple cysts were all benign, whereas mucinous cystic neoplasms, intraductal papillary mucinou

99 cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasms, serous cystadenomas, solid ps

100 ian Brenner tumors often are associated with mucinous cystic neoplasms, which are hypothesized to sha

101 Only few case reports of mucinous cystic pancreatic neoplasm containing an undiff

102 ly discriminate between SCA and premalignant mucinous cysts (intraductal papillary mucinous neoplasm

103 f 112 patients with histologically confirmed mucinous cysts of the pancreas evaluated in a single ter

104 Mucinous cysts require further differentiation to allow

105 osis and bile duct metaplasia with extensive mucinous cysts throughout all lobes, and induction of ch

106 None of the invasive cancers arising from mucinous cysts was <3 cm.

107 erence between benign mucinous and malignant mucinous cysts was observed (p = 0.025).

108 expressed in the cyst fluid of patients with mucinous cysts were CEA (median FI: IPMN 11.4, MCN 13.0,

109 gical assessment of predicting malignancy in mucinous cysts, particularly in small BD IPMN.

110 are benign and can be monitored clinically, mucinous cysts, such as intraductal papillary mucinous n

111 non-mucinous, benign mucinous, and malignant mucinous cysts.

112 gh-grade dysplastic cysts compared to benign mucinous cysts.

113 Scleromyxedema is a rare mucinous deposition disorder that shares clinical featur

114 of colonic stem cell markers LGR5 and PROM1, mucinous differentiation, and metastasis.

115 sis had been diagnosed with invasive serous, mucinous, endometrioid, or clear-cell carcinomas of the

116 r use of HRT was greater for serous than for mucinous, endometroid, or clear cell tumours (1.53 [1.31

117 .11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioi

118 ignificant association with disease stage in mucinous EOC subtypes (p = 0.009), lymph node involvemen

119 nd muscular hypertrophy, parietal cell loss, mucinous epithelial cell metaplasia, and massive eosinop

120 Invasive mucinous carcinoma of the ovary (mucinous epithelial ovarian cancer [mEOC]) is a histolog

121 at first birth was unassociated with risk of mucinous (for >/=30 years vs. 20-24 years, HR = 0.62, 95

122 e the most accurate test for differentiating mucinous from nonmucinous cystic lesions.

123 ponse to injury, PDG undergo an Shh-mediated mucinous gastrointestinal metaplasia with PanIN-like fea

124 al and phenotypic peculiarities: (i) CRIS-A: mucinous, glycolytic, enriched for microsatellite instab

125 Lubricin, a mucinous glycoprotein encoded by the PRG4 gene, provides

126 Mucin 1 (MUC1) is a mucinous glycoprotein expressed at the surfaces of epith

127 nt accompanied by a reduction in elastin and mucinous ground-substance content.

128 iated mucinous adenocarcinomas into a single mucinous high-grade category, is not known.

129 1.40]), high tumor grade (1.34 [1.16-1.55]), mucinous histological type (1.27 [1.08-1.50]), and nodal

130 pendiceal adenocarcinomas, of which 1375 had mucinous histology and 860 had nonmucinous histology.

131 The strikingly higher frequency of mucinous histology suggests that the biology of CRC diff

132 Advanced stage and mucinous histology were significant predictors of advers

133 ized by right-sided location, multifocality, mucinous histology, and lymphocytic infiltration.

134 ican Joint Committee on Cancer stage, signet/mucinous histology, and poor/undifferentiated grade.

135 1.14-2.34] and 4.94 (95% CI: 3.32-7.35) for mucinous histology, in comparison with 1.44 (95% CI: 0.8

136 nce of lymphovascular or perineural invasion,mucinous histology, number of vascular pedicles, and use

137 SMAD4 mutations were associated with mucinous histology.

138 ically poor - early stage cases and those of mucinous histology.

139 neoadjuvant chemotherapy, onset of PMs, and mucinous histology.

140 tis and multifocal, right-sided cancers with mucinous histopathology, similar to human MMR-deficient

141 oid and serous histotypes was higher than in mucinous histotypes, consistent with results of immunohi

142 Nkx2-1-negative murine lung tumors mimic mucinous human lung adenocarcinomas, which express gastr

143 Mucinous (intraductal mucinous neoplasm or mucinous cyst

144 carcinoma (Braf), endometrioid (Ctnnb1), or mucinous (Kras) carcinomas.

145 th formation of two distinct types of TC and mucinous lesions.

146 us), premalignant (mucinous), and malignant (mucinous) lesions.

147 duced morphogenesis of endometrioid-like and mucinous-like EOCs, respectively.

148 h' sensations [1], in part, by breaking down mucinous lubricating proteins in saliva [2,3].

149 12 weeks induced the expansion of PDGs with mucinous metaplasia and columnar cell atypia resembling

150 e architecture and chronic pancreatitis with mucinous metaplasia and increased formation of murine Pa

151 itis, acinar to ductal metaplasia (ADM), and mucinous metaplasia that resembles PanIN1a.

152 PDG may provide a link between Shh, mucinous metaplasia, and neoplasia.

153 nt of chronic inflammation, hyperplasia, and mucinous metaplasia, and, later in life, of pseudointest

154 ons (MDL) are called tubular complexes (TC), mucinous metaplasia, or pancreatic intraepithelial neopl

155 xpansion of the PDG compartment results in a mucinous metaplasia.

156 bular complexes and for lesions exhibiting a mucinous metaplasia.

157 fferentiation is identified in a minority of mucinous metaplastic lesions.

158 AREG levels for non-mucinous (n = 6), benign mucinous (n = 15), and cancerous cysts (n = 15) were 85

159 amples, the median (IQR) AREG levels for non-mucinous (n = 6), benign mucinous (n = 15), and cancerou

160 d a pancreatic lesion: intraductal papillary mucinous neoplasia (14 patients, 35%) and pancreatic duc

161 t of tumors resembling intraductal papillary mucinous neoplasia (IPMN), a precursor to PDAC in humans

162 malignant or invasive intraductal papillary mucinous neoplasia (IPMN).

163 ed a high incidence of intraductal papillary mucinous neoplasia and active fibrosis compared with Pdx

164 ient had a synchronous intraductal papillary mucinous neoplasia and pancreatic ductal adenocarcinoma.

165 enocarcinoma and 2 for intraductal papillary mucinous neoplasia), while the remaining 35 are under co

166 BACKGROUND & AIMS: Intraductal papillary mucinous neoplasias (IPMNs) are precancerous cystic lesi

167 compared with invasive intraductal papillary mucinous neoplasm (84.5% vs. 36%; P < 0.001).

168 (</=30 mm) branch-duct intraductal papillary mucinous neoplasm (BD IPMN; 67%), whereas also being spe

169 for the management of intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm we

170 nt of branch duct (BD) intraductal papillary mucinous neoplasm (IPMN) espouse safety of observation o

171 ic duct (MPD)-involved intraductal papillary mucinous neoplasm (IPMN) has been established by surgica

172 eatic branch-duct (BD) intraductal papillary mucinous neoplasm (IPMN) is infrequent and that extrapan

173 re similar to those of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.

174 neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) precursor lesions.

175 Human intraductal papillary mucinous neoplasm (IPMN) specimens were analyzed by immu

176 tic lesions resembling intraductal papillary mucinous neoplasm (IPMN) were observed as early as 2 mon

177 s preneoplastic lesion intraductal papillary mucinous neoplasm (IPMN), to find new microRNA (miRNA)-b

178 inoma in patients with intraductal papillary mucinous neoplasm (IPMN).

179 Intraductal papillary mucinous neoplasm (particularly the branch duct variant)

180 s cystic neoplasm =16, intraductal papillary mucinous neoplasm = 5, neuroendocrine tumors = 4), or 10

181 = 4), or 10 malignant (intraductal papillary mucinous neoplasm = 7, cystadenocarcinomas = 3) lesions.

182 ignant mucinous cysts (intraductal papillary mucinous neoplasm [IPMN], mucinous cystic neoplasm [MCN]

183 s for the treatment of intraductal papillary mucinous neoplasm and cystic lesions of the pancreas app

184 Intraductal papillary mucinous neoplasm and pancreatic neuroendocrine tumor bi

185 esection of pancreatic intraductal papillary mucinous neoplasm and to correlate recurrence and surviv

186 us cystic neoplasm and intraductal papillary mucinous neoplasm are superior to the original 2006 guid

187 ly one patient with an intraductal papillary mucinous neoplasm had high-grade dysplasia.

188 If the mucinous neoplasm is minimally invasive and cytoreductio

189 Mucinous (intraductal mucinous neoplasm or mucinous cystic neoplasm) lesions h

190 Intraductal papillary mucinous neoplasm patients appear to have cancer risk in

191 Invasive intraductal papillary mucinous neoplasm recurs frequently even after a complet

192 contrast, noninvasive intraductal papillary mucinous neoplasm recurs infrequently after resection, a

193 itonei (PMP) originating from an appendiceal mucinous neoplasm remains a biologically heterogeneous d

194 rs, two Brenner tumors not associated with a mucinous neoplasm, and two atypical proliferative (borde

195 nous cystic neoplasms, intraductal papillary mucinous neoplasm, cystic neuroendocrine tumors, and cys

196 In invasive intraductal papillary mucinous neoplasm, recurrence was similar after partial

197 Smad4 both regulate an intraductal papillary mucinous neoplasm-to-PDAC sequence through distinct tumo

198 ndocrine tumors (35%), intraductal papillary mucinous neoplasms (33%), solid pseudopapillary neoplasm

199 28, borderline 7), 22 intraductal papillary mucinous neoplasms (adenoma 9, borderline 9, cancer 4),

200 cially for branch duct intraductal papillary mucinous neoplasms (BD-IPMNs), remain uncertain.

201 lopment of branch duct intraductal papillary mucinous neoplasms (BD-IPMNs).

202 population of resected intraductal papillary mucinous neoplasms (IPMN) of the pancreas with respect t

203 for the management of intraductal papillary mucinous neoplasms (IPMN) recommend surgical treatment i

204 section for pancreatic intraductal papillary mucinous neoplasms (IPMN) using targeted next-generation

205 s, 2 cysts/remnants, 4 intraductal papillary mucinous neoplasms (IPMN), 2 adenocarcinomas, 1 low-grad

206 e origin of pancreatic intraductal papillary mucinous neoplasms (IPMN).

207 ations are reported in intraductal papillary mucinous neoplasms (IPMNs) and in McCune-Albright syndro

208 AC precursors known as intraductal papillary mucinous neoplasms (IPMNs) and predictors of their patho

209 Intraductal papillary mucinous neoplasms (IPMNs) are the most frequent cystic

210 iagnostic criterion of intraductal papillary mucinous neoplasms (IPMNs) involving the main duct (MD I

211 radiographic imaging, Intraductal Papillary Mucinous Neoplasms (IPMNs) of the pancreas are identifie

212 Intraductal papillary mucinous neoplasms (IPMNs) of the pancreas arising in br

213 molecular pathology of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas has not been

214 ed in association with intraductal papillary mucinous neoplasms (IPMNs) of the pancreas.

215 s cystadenomas (SCAs), intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (M

216 elines for branch-duct intraductal papillary mucinous neoplasms (IPMNs).

217 stic neoplasms (n=17), intraductal papillary mucinous neoplasms (n=15), serous cystadenomas (n=12), o

218 ative R0 microinvasive intraductal papillary mucinous neoplasms (without recurrence at 27, 29, and 34

219 ntified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreatic endocrine tumors).

220 asia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple intraepithelial neopl

221 ucinous cysts, such as intraductal papillary mucinous neoplasms and mucinous cystic neoplasms, have t

222 More cases of intraductal papillary mucinous neoplasms are being diagnosed and studied.

223 endocrine tumors, and intraductal pancreatic mucinous neoplasms are included.

224 Intraductal papillary mucinous neoplasms are increasingly diagnosed cystic pre

225 Intraductal papillary mucinous neoplasms are the most common pancreatic malign

226 ology should be retained for both serous and mucinous neoplasms because of the risk of extraovarian i

227 Intraductal papillary mucinous neoplasms can be multifocal and a potential cau

228 Mucinous neoplasms of the appendix were found in 5 of 17

229 carcinomas arising in intraductal papillary mucinous neoplasms of the pancreas (IPMN) by histologica

230 esions (ie, high-grade intraductal papillary mucinous neoplasms or grade 3 pancreatic intraepithelial

231 (4/58, 6.9%) than non- intraductal papillary mucinous neoplasms PDAC (5/385, 1.3%) (P = .02).

232 s of the treatment of intraductal pancreatic mucinous neoplasms shed some light on the management of

233 Appendiceal mucinous neoplasms sometimes present with peritoneal dis

234 inous cystic neoplasms+intraductal papillary mucinous neoplasms) from benign cystic lesions (serous c

235 adenocarcinoma, 17 had intraductal papillary mucinous neoplasms, 26 had symptomatic chronic pancreati

236 Pancreatic cysts may be intraductal mucinous neoplasms, mucinous cystic neoplasms, serous cy

237 a larger proportion of intraductal papillary mucinous neoplasms-related tumors (4/58, 6.9%) than non-

238 use pancreas to induce intraductal papillary mucinous neoplasms.

239 s on the treatment of intraductal pancreatic mucinous neoplasms.

240 ement of patients with Intraductal Papillary Mucinous Neoplasms.

241 the mouse pancreas and prevents formation of mucinous neoplasms.

242 r cystadenofibroma (n = 14; 11 serous, three mucinous); nonneoplastic cysts (n = 5; two endometriomas

243 noma, and the most frequent histotype is the mucinous one.

244 associations with endometrioid but not with mucinous or clear cell cancers.

245 tic infiltrate, and a poorly differentiated, mucinous or signet ring appearance.

246 moking may play a role in the development of mucinous ovarian cancer but not ovarian cancer of other

247 king is associated with an increased risk of mucinous ovarian cancer, but other studies have failed t

248 g had an almost 2.5 times' increased risk of mucinous ovarian cancer, such an increased risk was not

249 For mucinous ovarian cancer, the odds ratios were 1.5 (95% c

250 idence of serous invasive, endometrioid, and mucinous ovarian cancers in the US Nurses' Health Study

251 varian carcinomas but was negligible in both mucinous ovarian carcinomas and normal ovary.

252 mas at 12 weeks of age, recapitulating human mucinous ovarian tumors, which also exhibit heterozygous

253 denocarcinoma and high-grade dysplasia among mucinous pancreatic cysts are clinically needed.

254 paclitaxel is effective for the treatment of mucinous pancreatic cysts.

255 This pilot study demonstrates that non-mucinous PM of CRC can be visualized intraoperatively us

256 tential O-linked glycosylation sites on this mucinous protein.

257 These findings functionally link mucinous proteins with tumor aggression, and offer a new

258 tumorigenesis and inhibits Kras(G12D)-driven mucinous pulmonary adenocarcinoma.

259 not in PAFR-negative ovarian cells (HOSE and mucinous RMUG-L).

260 ing was associated with an increased risk of mucinous (RR per 20 pack-years, 1.26; 95% CI, 1.08 to 1.

261 Hispanics were more likely to have mucinous/signet-ring type histology (42.5%) than whites

262 utility of immunohistochemical subtyping of mucinous sweat gland carcinomas.

263 cinous adenocarcinoma of the skin," "primary mucinous sweat-gland carcinoma," and "endocrine mucin-pr

264 Lubricin is a mucinous, synovial fluid glycoprotein that enables near

265 urs of the two most common types, serous and mucinous, these having a different natural behaviour.

266 erefore, we present the first mouse model of mucinous tumor formation from ovarian cells and supporti

267 hotspot driver mutations specifically in the mucinous tumor.

268 Nine neoplasms were mucinous tumors (64.3%), including all neoplasms associa

269 rofiles in a series of intraductal papillary-mucinous tumors (IPMTs) of the pancreas, which represent

270 ce interval: 1.0, 2.4) but decreased risk of mucinous tumors (IRR = 0.3, 95% confidence interval: 0.1

271 Mucinous tumors (n = 18) were the most common malignant

272 d with an increased risk in endometrioid and mucinous tumors [e.g., testosterone, endometrioid tumors

273 us tumors is associated with size, and small mucinous tumors are very unlikely to be malignant.

274 Intraductal papillary mucinous tumors continue to be commonly encountered and

275 Malignancy within mucinous tumors is associated with size, and small mucin

276 Because mucinous tumors of the appendix similarly express MUC2,

277 iant was not significant overall, it was for mucinous tumors of the ovary, with an adjusted RR of 0.2

278 ordinate variants between paired Brenner and mucinous tumors supports a shared origin or progression.

279 demonstrated that a set of genes induced in mucinous tumors was shared with genes induced in a nontu

280 Nonmucinous but not mucinous tumors were significantly associated with menst

281 ily involving the ovary from primary ovarian mucinous tumors with peritoneal implants.

282 ations for serous tumors, KRAS mutations for mucinous tumors, and beta-catenin and PTEN mutations and

283 tones, localization of intraductal papillary mucinous tumors, and localization and treatment of hemob

284 Mucinous tumors, both borderline and invasive, were more

285 only 50% and 0% of clear cell carcinomas and mucinous tumors, respectively, were positive.

286 AS mutations in granulosa cell tumors and in mucinous tumors, respectively.

287 DNA from six Brenner tumors with paired mucinous tumors, two Brenner tumors not associated with

288 The risk of nonmucinous tumors, but not mucinous tumors, was positively associated with a family

289 erapy, whereas no association was found with mucinous tumors.

290 e a distinct subset of genes was specific to mucinous tumors.

291 ociation of NKX2-1 with the genes induced in mucinous tumors.

292 between ductal type of intraductal papillary mucinous tumors.

293 ely related to nonmucinous tumors but not to mucinous tumors.

294 l/Met variant of COMT decreases the risk for mucinous tumors.

295 perative sites and to destroy small residual mucinous tumour nodules, cytoreductive surgery is combin

296 The incidence of mucinous tumours (12% of the total) seemed little affect

297 of ovarian cancer, except for the intestinal mucinous type.

298 tive, double-blind trial of 39 patients with mucinous-type pancreatic cysts.

299 ociated with poorer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.8

300 a under the curve (0.79) for differentiating mucinous vs. nonmucinous cystic lesions.